Clinical trials: Oligo-Astrocytoma
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc
Glioma
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
- Trial name
- NCT00526812
- Testing
- RTA 744, RTA 744 injection
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Biogen
Malignant Glioma of Brain, Astrocytoma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma
- Trial name
- rQNestin (NCT03152318)
- Testing
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Glioma, Glioblastoma Multiforme
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma
- Trial name
- NCT00114309
- Testing
- 131-I-TM-601, 131I-TM601
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- TransMolecular
Brain Cancer, MALIGNANT GLIOMA
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
The best dose of radiation to be given with bevacizumab is currently unknown. This study will use higher doses of radiation with bevacizumab than have been used before.
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA)
- Trial name
- NCT01392209
- Testing
- Bevacizumab & Stereotactic Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Glioma (Diagnosis)
GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Oligo can help detect a specific molecular type of brain tumour called Oligodendroglioma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Oligodendroglioma, 1p19q Codeletion
- Trial name
- GliomaAI-Oligo (NCT07673705)
- Testing
- GliomaAI-Oligo
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Brain Cancer
Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients
This goal of this research study is to learn more about fatigue, sleep quality, and other symptoms in patients with primary brain tumors who are being treated with radiation therapy. Objectives: PRIMARY OBJECTIVE: 1.
- Trial name
- NCT00876499
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Astrocytoma, Oligo-Astrocytoma
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
This is a pilot vaccine study in adults with either WHO grade II astrocytoma, oligoastrocytoma or oligodendroglioma. The purpose of this study is test the safety and efficacy of an experimental tumor vaccine made from peptides…
- Conditions
- Astrocytoma, Oligo-Astrocytoma, Glioma
- Trial name
- NCT00795457
- Testing
- GAA/TT-peptide vaccine and poly-ICLC
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ian F. Pollack, M.D.